Fig. 3: In vitro cytotoxicity of P-LPK-CPT in CRC cells.
From: Anti-tumor effects of P-LPK-CPT, a peptide-camptothecin conjugate, in colorectal cancer
a–c Illustration of how the P-LPK-CPT conjugate was synthesized (Details reference to materials and methods). d The colonal forming capability after different treatments with the P-LPK-CPT conjugate of HCT116, LoVo and NCM460 cells. e Cell proliferation was measured by CCK-8 (n = 5, means ± SD, HCT116: CPT vs P-LPK-CPT, p = 0.0005; P-CON-CPT vs P-LPK-CPT, p = 0.0002; LoVo: CPT vs P-LPK-CPT, p < 0.0001; P-CON-CPT vs P-LPK-CPT, p = 0.0004) (**p < 0.01, ***p < 0.001, ****p < 0.0001). f The proportion of cells in the DNA synthesis state was qualified and one-way analysis of variance is used to test the difference between groups (n = 3, means ± SD, HCT116: CPT vs P-LPK-CPT, p = 0.0017; P-CON-CPT vs P-LPK-CPT, p = 0.0015; LoVo: CPT vs P-LPK-CPT, p = 0.0016; P-CON-CPT vs P-LPK-CPT, p = 0.0018) (**p < 0.01).
